Novonesis (Novozymes) A/S Cash Flow Conversion Efficiency

Latest as of March 2026: 0.015x

Novonesis (Novozymes) A/S cash flow conversion efficiency. Based on the latest financial reports, Novonesis (Novozymes) A/S (NSIS-B) has a cash flow conversion efficiency ratio of 0.015x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Dkr167.06 Million ≈ $26.14 Million USD) by net assets (Dkr10.92 Billion ≈ $1.71 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Novonesis (Novozymes) A/S worth for the company's overall valuation and market capitalisation.

Cash Flow Conversion Efficiency of Novonesis (Novozymes) A/S (2002–2025)

Cash flow conversion efficiency of Novonesis (Novozymes) A/S from 2002 to 2025. This chart illustrates how Novonesis (Novozymes) A/S's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Novonesis (Novozymes) A/S share price for real-time trading data and today's change.

Novonesis (Novozymes) A/S Cash Flow Conversion Ratio Explained

Novonesis (Novozymes) A/S cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Novonesis (Novozymes) A/S Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Novonesis (Novozymes) A/S ranked by their cash flow conversion efficiency. Review NSIS-B cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.

Company	Cash Flow Conversion Efficiency
STMicroelectronics NV ADR NYSE:STM	0.029x
Shinhan Financial Group Co Ltd NYSE:SHG	0.219x
Malayan Banking Bhd KLSE:1155	-0.198x
COSCO SHIPPING Holdings Co Ltd SHG:601919	0.022x
Martin Marietta Materials Inc NYSE:MLM	0.010x
CHINA PAC.IN.GR.GDR/5 YC1 F:75CB	N/A
Ameren Corp NYSE:AEE	0.056x
Alnylam Pharmaceuticals Inc NASDAQ:ALNY	0.207x

Annual Cash Flow Conversion Efficiency for Novonesis (Novozymes) A/S (2002–2025)

The table below shows the annual cash flow conversion efficiency of Novonesis (Novozymes) A/S from 2002 to 2025. Also see Novonesis (Novozymes) A/S assets under control for a full breakdown of the balance sheet.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Dkr10.86 Billion ≈ $1.70 Billion	Dkr1.22 Billion ≈ $191.11 Million	0.113x	+23.31%
2024-12-31	Dkr11.18 Billion ≈ $1.75 Billion	Dkr1.02 Billion ≈ $159.57 Million	0.091x	-68.46%
2023-12-31	Dkr14.35 Billion ≈ $2.25 Billion	Dkr4.15 Billion ≈ $649.61 Million	0.289x	+2.76%
2022-12-31	Dkr14.23 Billion ≈ $2.23 Billion	Dkr4.01 Billion ≈ $626.77 Million	0.282x	-15.39%
2021-12-31	Dkr12.21 Billion ≈ $1.91 Billion	Dkr4.06 Billion ≈ $635.53 Million	0.333x	-14.08%
2020-12-31	Dkr11.24 Billion ≈ $1.76 Billion	Dkr4.36 Billion ≈ $681.37 Million	0.387x	+39.12%
2019-12-31	Dkr11.48 Billion ≈ $1.80 Billion	Dkr3.20 Billion ≈ $500.04 Million	0.278x	-13.45%
2018-12-31	Dkr11.44 Billion ≈ $1.79 Billion	Dkr3.68 Billion ≈ $575.61 Million	0.322x	-10.80%
2017-12-31	Dkr11.27 Billion ≈ $1.76 Billion	Dkr4.06 Billion ≈ $635.69 Million	0.361x	+10.30%
2016-12-31	Dkr11.74 Billion ≈ $1.84 Billion	Dkr3.84 Billion ≈ $600.80 Million	0.327x	+13.52%
2015-12-31	Dkr11.59 Billion ≈ $1.81 Billion	Dkr3.34 Billion ≈ $522.41 Million	0.288x	-28.20%
2014-12-31	Dkr11.28 Billion ≈ $1.76 Billion	Dkr4.53 Billion ≈ $707.97 Million	0.401x	+70.80%
2013-12-31	Dkr11.07 Billion ≈ $1.73 Billion	Dkr2.60 Billion ≈ $406.63 Million	0.235x	-18.52%
2012-12-31	Dkr9.57 Billion ≈ $1.50 Billion	Dkr2.76 Billion ≈ $431.51 Million	0.288x	-6.11%
2011-12-31	Dkr8.82 Billion ≈ $1.38 Billion	Dkr2.71 Billion ≈ $423.84 Million	0.307x	+3.51%
2010-12-31	Dkr7.84 Billion ≈ $1.23 Billion	Dkr2.32 Billion ≈ $363.61 Million	0.297x	-4.50%
2009-12-31	Dkr5.85 Billion ≈ $915.43 Million	Dkr1.82 Billion ≈ $284.28 Million	0.311x	-18.09%
2008-12-31	Dkr4.48 Billion ≈ $700.30 Million	Dkr1.70 Billion ≈ $265.51 Million	0.379x	-18.89%
2007-12-31	Dkr3.67 Billion ≈ $573.73 Million	Dkr1.71 Billion ≈ $268.17 Million	0.467x	+3.39%
2006-12-31	Dkr3.39 Billion ≈ $530.86 Million	Dkr1.53 Billion ≈ $240.01 Million	0.452x	+29.36%
2005-12-31	Dkr3.79 Billion ≈ $593.60 Million	Dkr1.33 Billion ≈ $207.46 Million	0.349x	+5.69%
2004-12-31	Dkr3.89 Billion ≈ $608.93 Million	Dkr1.29 Billion ≈ $201.36 Million	0.331x	+0.48%
2003-12-31	Dkr4.17 Billion ≈ $653.21 Million	Dkr1.37 Billion ≈ $214.97 Million	0.329x	+18.38%
2002-12-31	Dkr4.25 Billion ≈ $664.63 Million	Dkr1.18 Billion ≈ $184.78 Million	0.278x	--

About Novonesis (Novozymes) A/S

CO:NSIS-B Denmark Specialty Chemicals

Market Cap

$30.27 Billion

Dkr193.46 Billion DKK

Market Cap Rank

#876 Global

#5 in Denmark

Share Price

Dkr469.00

Change (1 day)

+0.04%

52-Week Range

Dkr342.00 - Dkr481.50

All Time High

Dkr508.57